skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Concurrent Chemoradiotherapy With Helical Tomotherapy for Oropharyngeal Cancer: A Preliminary Result

Abstract

Purpose: To review the experience with and evaluate the treatment plan for helical tomotherapy for the treatment of oropharyngeal cancer. Methods and Materials: Between November 1, 2006 and January 31, 2009, 10 histologically confirmed oropharyngeal cancer patients were enrolled. All patients received definitive concurrent chemoradiation with helical tomotherapy. The prescription dose to the gross tumor planning target volume, the high-risk subclinical area, and the low-risk subclinical area was 70Gy, 63Gy, and 56Gy, respectively. During radiotherapy, all patients were treated with cisplatin, 30mg/m{sup 2}, plus 5-fluorouracil (425mg/m{sup 2})/leucovorin (30mg/m{sup 2}) intravenously weekly. Toxicity of treatment was scored according to the Common Terminology Criteria for Adverse Events, version 3.0. Several parameters, including maximal or median dose to critical organs, uniformity index, and conformal index, were evaluated from dose-volume histograms. Results: The mean survival was 18 months (range, 7-22 months). The actuarial overall survival, disease-free survival, locoregional control, and distant metastasis-free rates at 18 months were 67%, 70%, 80%, and 100%, respectively. The average for uniformity index and conformal index was 1.05 and 1.26, respectively. The mean of median dose for right side and left side parotid glands was 23.5 and 23.9Gy, respectively. No Grade 3 toxicity for dermatitis and body weight lossmore » and only one instance of Grade 3 mucositis were noted. Conclusion: Helical tomotherapy achieved encouraging clinical outcomes in patients with oropharyngeal carcinoma. Treatment toxicity was acceptable, even in the setting of concurrent chemotherapy. Long-term follow-up is needed to confirm these preliminary findings.« less

Authors:
 [1];  [1];  [2]
  1. Department of Radiation Oncology, Far Eastern Memorial Hospital, Taipei, Taiwan (China)
  2. Department of Otolaryngology, Far Eastern Memorial Hospital, Taipei, Taiwan (China)
Publication Date:
OSTI Identifier:
21436028
Resource Type:
Journal Article
Journal Name:
International Journal of Radiation Oncology, Biology and Physics
Additional Journal Information:
Journal Volume: 77; Journal Issue: 3; Other Information: DOI: 10.1016/j.ijrobp.2009.06.026; PII: S0360-3016 (09)00935-3; Copyright (c) 2010 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Journal ID: ISSN 0360-3016
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; CARCINOMAS; COMBINED THERAPY; COMPUTERIZED TOMOGRAPHY; CT-GUIDED RADIOTHERAPY; PHARYNX; BODY; DIAGNOSTIC TECHNIQUES; DIGESTIVE SYSTEM; DISEASES; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; ORGANS; RADIOLOGY; RADIOTHERAPY; RESPIRATORY SYSTEM; THERAPY; TOMOGRAPHY

Citation Formats

Shueng, Pei-Wei, Department of Radiation Oncology, National Defense Medical Center, Taipei, Taiwan, General Education Center, Oriental Technology Institute, Taipei, Taiwan, Wu, Le-Jung, and Chen, Shiou-Yi. Concurrent Chemoradiotherapy With Helical Tomotherapy for Oropharyngeal Cancer: A Preliminary Result. United States: N. p., 2010. Web. doi:10.1016/j.ijrobp.2009.06.026.
Shueng, Pei-Wei, Department of Radiation Oncology, National Defense Medical Center, Taipei, Taiwan, General Education Center, Oriental Technology Institute, Taipei, Taiwan, Wu, Le-Jung, & Chen, Shiou-Yi. Concurrent Chemoradiotherapy With Helical Tomotherapy for Oropharyngeal Cancer: A Preliminary Result. United States. https://doi.org/10.1016/j.ijrobp.2009.06.026
Shueng, Pei-Wei, Department of Radiation Oncology, National Defense Medical Center, Taipei, Taiwan, General Education Center, Oriental Technology Institute, Taipei, Taiwan, Wu, Le-Jung, and Chen, Shiou-Yi. 2010. "Concurrent Chemoradiotherapy With Helical Tomotherapy for Oropharyngeal Cancer: A Preliminary Result". United States. https://doi.org/10.1016/j.ijrobp.2009.06.026.
@article{osti_21436028,
title = {Concurrent Chemoradiotherapy With Helical Tomotherapy for Oropharyngeal Cancer: A Preliminary Result},
author = {Shueng, Pei-Wei and Department of Radiation Oncology, National Defense Medical Center, Taipei, Taiwan and General Education Center, Oriental Technology Institute, Taipei, Taiwan and Wu, Le-Jung and Chen, Shiou-Yi},
abstractNote = {Purpose: To review the experience with and evaluate the treatment plan for helical tomotherapy for the treatment of oropharyngeal cancer. Methods and Materials: Between November 1, 2006 and January 31, 2009, 10 histologically confirmed oropharyngeal cancer patients were enrolled. All patients received definitive concurrent chemoradiation with helical tomotherapy. The prescription dose to the gross tumor planning target volume, the high-risk subclinical area, and the low-risk subclinical area was 70Gy, 63Gy, and 56Gy, respectively. During radiotherapy, all patients were treated with cisplatin, 30mg/m{sup 2}, plus 5-fluorouracil (425mg/m{sup 2})/leucovorin (30mg/m{sup 2}) intravenously weekly. Toxicity of treatment was scored according to the Common Terminology Criteria for Adverse Events, version 3.0. Several parameters, including maximal or median dose to critical organs, uniformity index, and conformal index, were evaluated from dose-volume histograms. Results: The mean survival was 18 months (range, 7-22 months). The actuarial overall survival, disease-free survival, locoregional control, and distant metastasis-free rates at 18 months were 67%, 70%, 80%, and 100%, respectively. The average for uniformity index and conformal index was 1.05 and 1.26, respectively. The mean of median dose for right side and left side parotid glands was 23.5 and 23.9Gy, respectively. No Grade 3 toxicity for dermatitis and body weight loss and only one instance of Grade 3 mucositis were noted. Conclusion: Helical tomotherapy achieved encouraging clinical outcomes in patients with oropharyngeal carcinoma. Treatment toxicity was acceptable, even in the setting of concurrent chemotherapy. Long-term follow-up is needed to confirm these preliminary findings.},
doi = {10.1016/j.ijrobp.2009.06.026},
url = {https://www.osti.gov/biblio/21436028}, journal = {International Journal of Radiation Oncology, Biology and Physics},
issn = {0360-3016},
number = 3,
volume = 77,
place = {United States},
year = {Thu Jul 01 00:00:00 EDT 2010},
month = {Thu Jul 01 00:00:00 EDT 2010}
}